Post
Newsramp
newsramp.com
did:plc:xlsujlrwr5xpfxgaf4pixhri
Regentis Biomaterials (RGNT) has enrolled 43 of 80 patients in its Phase III GelrinC cartilage trial, targeting year-end completion. A new manufacturing process boosts yield 400%, and a $6.5M placement leaves the company debt-free with $9M cash. #RegenerativeMedicine #Biotech
2026-09-11T17:00:21.670Z